Intraoperative cell salvage

[1]

Why this is examined / the one-line answer

Intraoperative cell salvage (ICS) is core patient blood management (PBM) technology. It appears in arthroplasty revision, major spine, cardiac/aortic, obstetrics, trauma, liver, and Jehovah’s Witness / blood-refusal stems. Examiners do not want a brochure on machine brands. They want: when you set it up, what actually comes back, what it cannot do, and how you integrate it with TXA, haemostasis, and allogeneic MTP when loss is catastrophic.[1][2]

One-liner: I deploy ICS when adult expected blood loss is substantial or allogeneic transfusion is likely, reinfuse washed autologous RBCs via a trained continuous pathway, and plan factors/platelets/VET separately because salvage is not whole blood. [1]

Association of Anaesthetists 2018 cell salvage guidance is the named UK/ANZ-relevant practice framework examiners recognise; BJA reviews frame ICS inside broader conservation strategy.[1][2]

Preoperative assessment and decision to use ICS

Indications that pass exams

Use ICS when it is likely to reduce allogeneic red-cell exposure: [1]

Also consider postoperative cell salvage only where local evidence and device type support it — do not conflate washed intraoperative systems with unwashed drain reinfusion without nuance.[1]

Consent and documentation

Explain: autologous washed red cells from the field; residual risks (contamination, air, process error); that bank blood may still be needed; that platelets and clotting factors are washed away. Document Jehovah’s Witness continuous-circuit preferences precisely (see blood-refusal topic).[1]

Contraindications and cautions (say “relative” honestly)

• Frank bacterial contamination / purulent field — usually avoid reinfusion risk of bacteraemia.
• Amniotic fluid / gross bowel content — follow local SOP; many units use separate suckers and strict wash; obstetrics has evolved practice with leucodepletion filters in some protocols.
• Malignancy — theoretical reinfusion of tumour cells; many centres still use ICS selectively (e.g. with leucodepletion) after consent and MDT context — do not give absolute dogma without local policy.[1][2]
• Sickle cell disease — specialised caution (sickling risk in circuit) — escalate haematology advice.
• Patient refusal of autologous reinfusion — respect documented wishes.

Applied technology — the viva gold

Sequence (draw it)

1. Collection — dedicated sucker with anticoagulant (commonly heparinised saline) mixed at the tip/reservoir.
2. Reservoir + filter — defoaming, debris filtration.
3. Wash / centrifuge — plasma, free Hb fraction, anticoagulant, and most platelets/factors removed; RBC concentrate produced.
4. Reinfusion — through a giving set with appropriate filter; no air; labelled autologous. [1]

Product identity: washed autologous red cells (Hct often roughly mid–high 50s depending on machine/settings — know that it varies). Not returned in clinically useful amounts: platelets, plasma coagulation factors, plasma proteins.[2]

Quality killers examiners love

• Excessive vacuum → haemolysis.
• Wrong or inadequate anticoagulant → clots in reservoir.
• Delayed processing of full bowls → quality and bacterial risk concerns.
• Contaminant sucker (cement, irrigation fluid, faeces, urine) into the blood sucker.
• Untrained intermittent operators — ICS is a process, not a button. [1]

[1]

Anaesthetic goals

1. Right case, right time — set up before the blood hits the floor when possible.
2. Trained operator and machine check.
3. Minimise allogeneic RBC exposure without ignoring coagulopathy.
4. Combine with TXA (where indicated), temperature control, surgical haemostasis, and restrictive allogeneic thresholds in appropriate cohorts.[3]
5. Document volumes salvaged and reinfused.

Technique options and decision matrix

Monitoring and equipment

Machine and disposables check before incision when feasible: reservoir, bowl, wash fluid, anticoagulant mix, vacuum limit, reinfusion bag labelling. [1]

Patient side: standard monitoring; point-of-care Hb if large loss; temperature; consider VET (ROTEM/TEG) and formal coagulation when wash volumes are large or bleeding is microvascular. [1]

Backup: allogeneic blood available unless pure blood-refusal pathway with clear limits; cell salvage failure plan stated aloud. [1]

Intraoperative management — worked sequence

1. Decide ICS at team brief; assign operator.
2. Start collection early — waiting until 1 L on the floor wastes yield.
3. Separate blood sucker from contaminant/irrigation sucker when practical.
4. Process bowls as they fill; reinfuse promptly via filtered line; watch for air.
5. Track cumulative reinfused volume; if multi-litre, think coagulopathy and check VET/labs.
6. Use allogeneic RBCs only to indication — cardiac restrictive strategies (e.g. TRICS III context) remind examiners that more red cells are not always better, but that is threshold philosophy, not a reason to skip salvage when it reduces exposure.[3]
7. Continue surgical haemostasis and TXA pathways as indicated.

Worked numbers (exam style)

Adult revision hip: EBL 1200 mL → salvage may return a clinically useful autologous RBC volume after wash losses (wash yield is incomplete — expect less than “all blood lost”). If microvascular ooze persists with Hb 95 g/L after reinfusion, the problem is often coagulation/temperature/surgery, not “more washed RBCs”. [1]

Crisis pivots

Machine failure mid-case

Declare; switch to allogeneic pathway / blood-refusal alternatives; do not leave unprocessed reservoir blood sitting without a plan. [1]

Coagulopathy after multi-litre wash

Treat as dilutional/consumptive picture: plasma, platelets, fibrinogen (or cryoprecipitate), calcium, temperature, surgical control, VET-guided therapy — not endless RBC bowls alone. [1]

Contaminated product suspected

Stop reinfusion; quarantine product; document; continue with bank blood if accepted; review process. [1]

Air in line / suspected air embolism

Stop infusion; standard air embolism management (prevent further air, 100% O2, support circulation, left lateral/head-down debates secondary to life support); check clamps and bag. [1]

Acute transfusion-type reaction to autologous product

Rare but process contaminants exist — stop, treat as reaction pathway, investigate. [1]

Postoperative plan

Document volumes collected/reinfused and any discarded product. Continue Hb trajectory monitoring. Do not automatically reinfuse postoperative drains as “the same as ICS” — device and evidence differ. Hand over ongoing bleeding risk and coagulation plan. [1]

Special populations

Obstetrics: washed ICS increasingly accepted; local leucodepletion filter policies and anti-D for Rh-negative mothers matter; amniotic fluid concerns are mitigated by wash/SOP but remain viva fodder.[1]

Paediatrics: different volume thresholds and equipment; specialist practice. [1]

Sepsis / contaminated surgery: relative contraindication to reinfusion. [1]

Cancer: individualised consent and policy — state uncertainty honestly. [1]

Cardiac surgery: ICS common; still manage CPB coagulopathy separately; restrictive allogeneic thresholds may apply to bank blood decisions.[3]

Jehovah’s Witness: continuous circuit often acceptable when discontinuous bank transfusion is not — confirm in writing.[1]

SAQ answer scaffold

Outline the role of intraoperative cell salvage in major orthopaedic revision surgery. [1]

1. Definition/process (3): collect–wash–reinfuse autologous RBCs; trained operator.[2]
2. Indications (2): EBL often >500 mL adult / likely transfusion; antibodies; blood refusal pathways.[1]
3. Limitations (3): no platelets/factors; quality depends on suction/anticoagulant; not MTP.
4. Cautions (2): infection, malignancy policy, contamination, consent.
5. Integration (3): TXA, haemostasis, temperature, restrictive allogeneic use, coagulation monitoring.

Viva stem bank and model phrases

Stem 1: “When do you set up cell salvage?”
Model: “When adult blood loss is expected to be significant — commonly taught around more than 500 mL — or allogeneic transfusion is likely, and in special serology or blood-refusal pathways.”[1]

Stem 2: “What do you reinfuse?”
Model: “Washed autologous red cells. Not a useful platelet or clotting-factor product.” [1]

Stem 3: “Why might they still bleed after three bowls?”
Model: “Wash removes plasma and platelets; temperature and surgical bleeding may persist — I check coagulation/VET and treat factors, not only Hb.” [1]

Stem 4: “Cancer surgery — yes or no?”
Model: “Individualised. Theoretical tumour-cell concern exists; many units use ICS selectively with consent and local policy rather than absolute prohibition.”[1]

Stem 5: “Jehovah’s Witness accepts continuous circuit only.”
Model: “I keep an unbroken circuit from collection to reinfusion if that matches their documented acceptance, and maximise all other conservation measures.” [1]

Stem 6: “Obstetric haemorrhage — any special points?”
Model: “Washed ICS is increasingly used with local SOPs and filter policies; coordinate anti-D and communicate with the obstetric team.”[1]

Stem 7: “Does salvage replace a group and screen?”
Model: “No. ICS fails, yields are incomplete, and coagulopathy needs components — bank blood pathways remain unless refused.” [1]

Common traps

• Calling salvaged blood “whole blood”
• No coagulopathy plan after large-volume wash
• Starting collection too late
• High suction haemolysis / wrong anticoagulant
• Reinfusing grossly contaminated product
• Ignoring consent nuances in blood refusal
• Treating ICS as a reason to skip TXA or surgical haemostasis
• Conflating unwashed drain reinfusion with washed ICS evidence [1]

[1] [1] [1] [1]

Examiner mental map

1. Indicate correctly (volume/transfusion risk/special groups).
2. Describe process and product identity.
3. List quality killers and cautions (infection, cancer, obstetrics).
4. Coagulopathy after wash — factors/platelets/VET.
5. Integrate PBM (TXA, temperature, restrictive bank blood).
6. Blood-refusal continuous circuit documentation. [1]

If you hit those six without selling the machine, you pass the cell-salvage viva. [1]

References

1. [1]Klein AA, Bailey CR, Charlton AJ, et al. Association of Anaesthetists guidelines: cell salvage for peri-operative blood conservation 2018 Anaesthesia, 2018.PMID 29989144
2. [2]Ashworth A, Klein AA Cell salvage as part of a blood conservation strategy in anaesthesia Br J Anaesth, 2010.PMID 20802228
3. [3]Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery N Engl J Med, 2017.PMID 29130845